Evotec SE (0IRF) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Evotec SE €0.42, price €2.92, upside -85.6%, quality 44 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range €2.76 – €45.18 · fair‑value band €0.3800 – €0.4600 · the €2.92 price screens above the €0.4200 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics.
Show more
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. In addition, it has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. Further, the company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. Evotec SE has strategic collaboration with Almirall, S.A. for the development of novel therapeutics for severe skin diseases, including a range of immune-mediated inflammatory conditions. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Stock analysis
Evotec SE (0IRF) currently trades at €2.92, while our model-based Fair Value estimate is €0.4200, 85.6% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of €1.14 per share, and 0 of the 23 models we run sit above the €2.92 price.
Bear case: the Multiples group reads lowest at €0.0700, and 23 of the 23 models stay below the price. Evidence for this calculation is high.
Scenario range: €0.3800 (bear) to €0.4600 (bull), the price of €2.92 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Evotec SE reported revenue of €501M in FY2020 versus €165M in FY2016, a compound +32.1%/yr. Reported net income was €6.3M in FY2020, compounding −31.0%/yr from FY2016.
Key figures
Market cap €5.4B · P/S ratio 7.27 · Net margin 1.2% · Return on equity −24.1% · Return on assets (EBIT) 6.6% · Operating margin −29.6% · Revenue (TTM) €745M · Revenue growth (YoY) −21.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 59% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −86%, 0IRF screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (€0.0600 to €1.82). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear €0.3800Fair Value €0.4200Bull €0.4600
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.82/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+12.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.8%
’16
’17
’18
’19
’20
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
19.1% (2016) → 9.7% (2020)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no share-count history
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Evotec SE Fair Value". https://www.fairvalue-calculator.com/stock/0IRF
Frequently asked questions
Is Evotec SE (0IRF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of €0.4200 versus a price of €2.92, about −86% upside (overvalued).
What is the fair value of 0IRF?
Our model-based fair value for Evotec SE is €0.4200 (as of Sep 24, 2026), built from audited fundamentals. The current price: €2.92.
What is the quality score of 0IRF?
Evotec SE has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Evotec SE (0IRF)?
Our model-based price target is the fair value of €0.4200 (as of Sep 24, 2026) from 23 valuation models. Cautious scenario €0.3800, optimistic scenario €0.4600. It is a calculation from audited fundamentals, not an analyst target.
What is the Evotec SE stock forecast for 2026?
Our models put fair value at €0.4200, about −86% upside versus a price of €2.92 (overvalued). Cautious scenario €0.3800, optimistic scenario €0.4600. The calculation is refreshed regularly with new filings.
What is the revenue of Evotec SE (0IRF)?
Evotec SE reported trailing-twelve-month revenue of about €745M (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Evotec SE (0IRF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Evotec SE it is €0.4200 per share (as of Sep 24, 2026), against a price of €2.92. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is Evotec SE stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0IRF trades above its calculated fair value: price €2.92, fair value €0.4200, a gap of about −86% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0IRF?
No. The price is what the market pays today (€2.92); the fair value is what the company's own numbers justify (€0.4200). For Evotec SE the two are €2.50 per share apart. That gap is exactly why we show both numbers side by side.
How much is Evotec SE worth?
The market values Evotec SE at about €5.4B (market capitalisation, as of Sep 24, 2026). Per share that is €2.92; our models calculate a fair value of €0.4200 per share.
What do the bullish and bearish scenarios say about 0IRF?
Our models span a range for Evotec SE: cautious scenario €0.3800, base €0.4200, optimistic €0.4600 per share (as of Sep 24, 2026, price €2.92). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 0IRF from its 52-week high?
Evotec SE trades at €2.92, about 59% below its 52-week high of €7.14 and 6% above the low of €2.76 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of €0.4200 is for.
Which stocks are comparable to Evotec SE?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Evotec SE stock attractive at the current price?
The data as of Sep 24, 2026: price €2.92, calculated fair value €0.4200 (−86%), Quality Score 44/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0IRF calculated?
We run Evotec SE through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €0.4200, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Evotec SE itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Evotec SE (0IRF)?
The closing price on Oct 2, 2026 was €2.92. Our model-based fair value is €0.4200, about −86% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Evotec SE right now?
The price sits above even our optimistic bull case (€0.4600). The favourable scenario is already priced in. Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts.
Key figures of Evotec SE
How large is the market capitalisation of Evotec SE (0IRF)?
The market capitalisation of Evotec SE is €5.4B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Evotec SE (0IRF)?
The price-to-sales ratio of Evotec SE is 7.27 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Evotec SE (0IRF)?
The net margin of Evotec SE is 1.2% (fiscal year 2020). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Evotec SE (0IRF)?
The return on equity (ROE) of Evotec SE is −24.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Evotec SE (0IRF)?
On an EBIT basis the return on assets of Evotec SE is 6.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Evotec SE (0IRF)?
The operating margin of Evotec SE is −29.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Evotec SE (0IRF)?
Revenue at Evotec SE is growing −21.7% versus a year earlier (3y avg +23.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
